Published ResearchSummary
The Respiragene™ test developed and validated by Molecular Diagnostics Laboratories LLC is derived from patent-protected and proprietary discoveries that show that a specific combination of genetic markers can be measured to determine an individual's risk, as compared with other smokers, of developing lung cancer. Extensive and ongoing clinical studies continue to demonstrat the analytical validty of Repiragene™ and its utility for doctors caring for smokers and ex-smokers.
Lung cancer susceptibility score and SNP panel
Young Robert P. et al. Functional variants of anti-oxidant genes in smokers with COPD and in those with normal lung function. Thorax 2006; 30: 1-7.
Young RP, Hopkins RJ, Hay BJ, et al. Lung cancer gene associated with COPD: triple whammy or possible confounding effect?. Eur Respir J 2008; 32: 1158-1164.
Young RP, Hopkins RJ, Eaton TE. Forced Expiratory Volume in one second: not just a lung function test but a marker of premature death from all causes. Eur Respir J 2007; 30(4): 616-622.
Possible therapeutic interventions in high risk smokers
Young RP, Hopkins RJ, Eaton TE. Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. Postgraduate Medical Journal 2009
Young RP, Hopkins RJ, Smith M, Hogarth, DK. Smoking cessation: the potential role of risk assessment tools as motivational triggers. Postgraduate Medical Journal 2010; 86:26-33.
General Articles
Young RP, Hopkins RJ, Hay BA, Epton MJ, Mills GD, et al. A gene-based risk score for lung cancer susceptibility in smokers and ex-smokers. Postgraduate Medical Journal 2009
Young, RP, R Hopkins and TE Eaton Pharmacological actions of statins: potential utility in COPD. European Respiratory Review 2009;18: 222-232.
Events
- Philadelphia, PA, September 29-30, 2009. Analyzing the current scenario and examining new smoking..
- Zhuhai, China - October 24-25, 2009
- Hilton Americas-Houston, Houston, TX, December 6-9, 2009.
- March 20-24, 2010 in Brisbane, Australia
- New Orleans, Louisiana, May 14-19, 2010.
Presentations & Updates
-
A recently published study by independent researchers from the NIH (Sanderson, et al, Cancer Epidemilogy, Biomarkers & Prevention) 1 has highlighted current smokers’ interest in, and responsiveness to, genetic information allows them to better understand their personal risk of developing lung cancer...
-
In June-October 2009, a pilot survey was conducted among 43 smokers in Auckland, New Zealand to assess the impact of taking the Respiragene™ test on attitudes and behaviour associated with quitting smoking.
-
The ability of the Respiragene™ test to identify smokers at greatest risk of developing lung cancer has been further validated by results of a large-scale prospective study of smokers in Auckland, New Zealand.